KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Assets (2016 - 2025)

Historic Assets for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $1.4 billion.

  • Neogenomics' Assets fell 1698.42% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year decrease of 1698.42%. This contributed to the annual value of $1.4 billion for FY2025, which is 1698.42% down from last year.
  • As of Q4 2025, Neogenomics' Assets stood at $1.4 billion, which was down 1698.42% from $1.4 billion recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Assets ranged from a high of $1.9 billion in Q3 2021 and a low of $1.4 billion during Q4 2025
  • Its 5-year average for Assets is $1.7 billion, with a median of $1.7 billion in 2023.
  • As far as peak fluctuations go, Neogenomics' Assets skyrocketed by 621681.76% in 2021, and later tumbled by 1698.42% in 2025.
  • Over the past 5 years, Neogenomics' Assets (Quarter) stood at $1.9 billion in 2021, then dropped by 6.94% to $1.7 billion in 2022, then fell by 3.38% to $1.7 billion in 2023, then fell by 2.57% to $1.6 billion in 2024, then decreased by 16.98% to $1.4 billion in 2025.
  • Its Assets was $1.4 billion in Q4 2025, compared to $1.4 billion in Q3 2025 and $1.4 billion in Q2 2025.